UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

CNS drugs, 2021-03, Vol.35 (3), p.317-330

2021

Volltextzugriff (PDF)

Essential role of limiting telomeres in the pathogenesis of Werner syndrome

Nature genetics, 2004-08, Vol.36 (8), p.877-882

2004

Volltextzugriff (PDF)

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Multiple sclerosis, 2022-06, Vol.28 (7), p.1131-1137

2022

Volltextzugriff (PDF)

Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks

Proceedings of the National Academy of Sciences - PNAS, 2016-06, Vol.113 (26), p.E3667-E3675

2016

Volltextzugriff (PDF)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

Therapeutic advances in neurological disorders, 2021-01, Vol.14, p.1756286420975916-1756286420975916

2021

Volltextzugriff (PDF)

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program

Multiple sclerosis and related disorders, 2022-01, Vol.57, p.103350-103350, Article 103350

2022

Volltextzugriff (PDF)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

Therapeutic advances in neurological disorders, 2021-01, Vol.14, p.1756286420975227-1756286420975227

2021

Volltextzugriff (PDF)

RAD51-Dependent Break-Induced Replication Differs in Kinetics and Checkpoint Responses from RAD51-Mediated Gene Conversion

Molecular and Cellular Biology, 2005-02, Vol.25 (3), p.933-944

2005

Volltextzugriff (PDF)

Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN

Multiple sclerosis and related disorders, 2022-01, Vol.57, p.103367-103367, Article 103367

2022

Volltextzugriff (PDF)

Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide

Multiple sclerosis and related disorders, 2020-05, Vol.40, p.101954-101954, Article 101954

2020

Volltextzugriff (PDF)

Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression

Genes & development, 2003-01, Vol.17 (1), p.88-100

2003

Volltextzugriff (PDF)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418795085-1756286418795085

2018

Volltextzugriff (PDF)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418791143-1756286418791143

2018

Volltextzugriff (PDF)

Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study

Med (New York, N.Y. : Online), 2022-09, Vol.3 (9), p.612-621.e3

2022

Volltextzugriff (PDF)

Mrc1 Phosphorylation in Response to DNA Replication Stress Is Required for Mec1 Accumulation at the Stalled Fork

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.12765-12770

2009

Volltextzugriff (PDF)

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

Neurology and therapy, 2021-06, Vol.10 (1), p.251-263

2021

Volltextzugriff (PDF)

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

Multiple sclerosis journal - experimental, translational and clinical, 2023-04, Vol.9 (2), p.20552173231169463-20552173231169463

2023

Volltextzugriff (PDF)

DNA-Dependent Protein Kinase Catalytic Subunit Is Not Required for Dysfunctional Telomere Fusion and Checkpoint Response in the Telomerase-Deficient Mouse

Molecular and Cellular Biology, 2007-03, Vol.27 (6), p.2253-2265

2007

Volltextzugriff (PDF)

Comparison of Pharmacokinetic Profiles and Safety Outcomes with Peginterferon Beta-1a Administration in Black/African American and White Participants (P4-4.009)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

1111 Increasing access and quality of care for individuals from underrepresented communities living with lupus: insights from qualitative interviews with patients and physicians

Lupus science & medicine, 2021-11, Vol.8 (Suppl 2), p.A38-A39

2021

Volltextzugriff (PDF)

Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS (2392)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

Journal of neurology, 2020-06, Vol.267 (6), p.1715-1723

2020

Volltextzugriff (PDF)

Peginterferon Beta-1a Demonstrated Better Clinical Outcomes Than Teriflunomide in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients: A Matching-Adjusted Comparison of Phase 3 Trial Data (P1.360)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE

Revue neurologique, 2019-04, Vol.175, p.S96-S96

2019

Volltextzugriff (PDF)

1 – 25 von 196

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(162)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Essential role of limiting telomeres in the pathogenesis of Werner syndrome

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

RAD51-Dependent Break-Induced Replication Differs in Kinetics and Checkpoint Responses from RAD51-Mediated Gene Conversion

Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN

Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide

Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study

Mrc1 Phosphorylation in Response to DNA Replication Stress Is Required for Mec1 Accumulation at the Stalled Fork

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

DNA-Dependent Protein Kinase Catalytic Subunit Is Not Required for Dysfunctional Telomere Fusion and Checkpoint Response in the Telomerase-Deficient Mouse

Comparison of Pharmacokinetic Profiles and Safety Outcomes with Peginterferon Beta-1a Administration in Black/African American and White Participants (P4-4.009)

1111 Increasing access and quality of care for individuals from underrepresented communities living with lupus: insights from qualitative interviews with patients and physicians

Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS (2392)

Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

Peginterferon Beta-1a Demonstrated Better Clinical Outcomes Than Teriflunomide in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients: A Matching-Adjusted Comparison of Phase 3 Trial Data (P1.360)

Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE

Suchergebnisse filtern